Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22657962 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL14713434 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL29444978 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL29521618 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL19725973 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL23194379 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL14981499 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL16329452 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL16329449 | 0.99 | GAA (0.33) | CRBNMGMTGAA | |
| SCHEMBL26846799 | 0.93 | CRBN (0.36) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215321-A2 | POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES | CONFLUENCE THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| US-20260133115-A1 | MASS CYTOMETRY REAGENTS AND METHODS FOR SIGNAL AMPLIFICATION | STANDARD BIOTOOLS CANADA INC. (CA) | 2026-05-14 | — | — | US | disclosed |
| US-12540893-B2 | Mass cytometry reagents and methods for signal amplification | STANDARD BIOTOOLS CANADA INC. (CA) | 2026-02-03 | — | — | US | disclosed |
| EP-3704133-B1 | REAGENTS AND METHODS FOR ELEMENTAL IMAGING MASS SPECTROMETRY OF BIOLOGICAL SAMPLES | STANDARD BIOTOOLS CANADA INC (CA) | 2025-10-01 | — | — | EP | disclosed |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-12364791-B2 | Conformal coating of biological surfaces | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-22 | — | — | US | disclosed |
| WO-2025121429-A1 | Fc-CELL COMPLEX AND METHOD FOR PRODUCING THE SAME | 味の素株式会社 | 2025-06-12 | — | — | WO | disclosed |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-12188939-B2 | Super-resolution optical microscopy using aluminosilicate nanoparticles | CORNELL UNIVERSITY (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240345072-A1 | REAGENTS AND METHODS FOR ELEMENTAL IMAGING MASS SPECTROMETRY OF BIOLOGICAL SAMPLES | STANDARD BIOTOOLS CANADA INC. (CA) | 2024-10-17 | — | — | US | disclosed |
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-115135680-A | Mass cytometry reagents and methods for signal amplification | 标准生物工具加拿大公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022078566-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-04-21 | — | — | WO | disclosed |
| US-20220113315-A1 | SUPER-RESOLUTION OPTICAL MICROSCOPY USING ALUMINOSILICATE NANOPARTICLES | CORNELL UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20180127822-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9828633-B1 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9206216-B2 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20120252691-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | MC2R, OGFR, GLS | CRBN 3588/4885MGMT 2237/4885GAA 3194/4885 |
| US-20180127822-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | RNGTT, NUDT1, ADAR | CRBN 1443/4885MGMT 683/4885GAA 1293/4885 |
| US-12188939-B2 | Super-resolution optical microscopy using aluminosilicate nanoparticles | SEPTIN9, NUP50, FLOT1 | CRBN 1439/4885MGMT 2704/4885GAA 2279/4885 |
| US-20120252691-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | RNGTT, NUDT1, ADAR | CRBN 1443/4885MGMT 683/4885GAA 1293/4885 |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | CRBN 1374/4885MGMT 2456/4885GAA 3329/4885 |
| US-12540893-B2 | Mass cytometry reagents and methods for signal amplification | CD47, HLCS, SRMS | CRBN 393/4885MGMT 3638/4885GAA 4440/4885 |
| US-20260133115-A1 | MASS CYTOMETRY REAGENTS AND METHODS FOR SIGNAL AMPLIFICATION | SRMS, THOC2, TSPO | CRBN 176/4885MGMT 3905/4885GAA 4885/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | CRBN 979/4885MGMT 2029/4885GAA 553/4885 |
| US-20240345072-A1 | REAGENTS AND METHODS FOR ELEMENTAL IMAGING MASS SPECTROMETRY OF BIOLOGICAL SAMPLES | SRMS, GPX4, SGMS2 | CRBN 679/4885MGMT 240/4885GAA 1638/4885 |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | CRBN 1374/4885MGMT 2456/4885GAA 3329/4885 |
| US-20220113315-A1 | SUPER-RESOLUTION OPTICAL MICROSCOPY USING ALUMINOSILICATE NANOPARTICLES | SEPTIN9, NUP50, FLOT1 | CRBN 1439/4885MGMT 2704/4885GAA 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.